Finally, we have proposed for the first time that the BH3-mimetic drug ABT-263, which was specifically designed to inhibit pro-survival BCL2 family proteins, and has shown significant efficacy in preclinical xenograft models of ALL [29–31], may play a potential role in the treatment of GC-resistant ALL cells. Here, BCL2 is linked to acute lymphoblastic leukemia.